Get the Stockscreener App
33.29
4.64%
-1.62
After Hours:
33.47
0.18
+0.54%
Alkermes Plc stock is traded at $33.29, with a volume of 1.84M.
It is down -4.64% in the last 24 hours and up +12.39% over the past month.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$34.91
Open:
$33.33
24h Volume:
1.84M
Relative Volume:
0.89
Market Cap:
$5.50B
Revenue:
$1.51B
Net Income/Loss:
$333.35M
P/E Ratio:
17.07
EPS:
1.95
Net Cash Flow:
$315.22M
1W Performance:
-0.77%
1M Performance:
+12.39%
6M Performance:
+21.36%
1Y Performance:
-0.63%
1-Day Range:
$33.04
$34.22
1-Week Range:
$33.04
$35.34
52-Week Range:
$25.16
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Name
Alkermes Plc
Sector
Phone
00-353-1-772-8000
Address
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
33.29 | 5.76B | 1.51B | 333.35M | 315.22M | 1.95 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.37 | 57.75B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.64 | 56.70B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.16 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.92 | 39.96B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
476.13 | 20.49B | 3.13B | 1.27B | 1.12B | 26.39 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-25 | Initiated | Truist | Buy |
| Sep-26-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-03-25 | Initiated | Wells Fargo | Overweight |
| Jul-15-25 | Initiated | Goldman | Buy |
| Jun-17-25 | Upgrade | UBS | Neutral → Buy |
| May-28-25 | Initiated | Needham | Buy |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-04-25 | Upgrade | UBS | Sell → Neutral |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Nov-05-24 | Upgrade | Stifel | Hold → Buy |
| Jun-17-24 | Initiated | TD Cowen | Buy |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-20-24 | Downgrade | UBS | Neutral → Sell |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Oct-24-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-17-23 | Initiated | UBS | Neutral |
| Nov-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-14-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-16-22 | Initiated | Piper Sandler | Neutral |
| Apr-22-22 | Resumed | Goldman | Buy |
| Apr-20-22 | Initiated | Goldman | Buy |
| Jan-27-22 | Upgrade | Cantor Fitzgerald | Hold → Overweight |
| Dec-01-21 | Initiated | Citigroup | Neutral |
| Oct-07-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-02-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-20 | Upgrade | Mizuho | Neutral → Buy |
| Jul-30-20 | Downgrade | Goldman | Neutral → Sell |
| Feb-14-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-14-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Jan-31-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-15-19 | Upgrade | Goldman | Sell → Neutral |
| May-31-19 | Initiated | H.C. Wainwright | Neutral |
| May-01-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Downgrade | Goldman | Neutral → Sell |
| Dec-14-18 | Initiated | Wolfe Research | Underperform |
| Dec-13-18 | Downgrade | Credit Suisse | Outperform → Underperform |
| Nov-05-18 | Initiated | Piper Jaffray | Neutral |
| Aug-07-18 | Initiated | Stifel | Hold |
| Jun-21-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-06-18 | Initiated | B. Riley FBR, Inc. | Buy |
| May-16-18 | Upgrade | Citigroup | Neutral → Buy |
| May-11-18 | Initiated | BofA/Merrill | Buy |
View All
Alkermes Plc Stock (ALKS) Latest News
Alkermes plc completes acquisition of Avadel Pharmaceuticals plc, accelerating entry into sleep medicine market - marketscreener.com
MDGL Strengthens MASH Franchise With New Genetic Approaches - Finviz
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market - BioSpace
Alkermes PLC Completes Acquisition Of Avadel Pharmaceuticals PLC, Accelerating Entry Into Sleep Medicine Market - TradingView
Alkermes Acquires Avadel Pharmaceuticals - Contract Pharma
Alkermes, Inc. , Alkermes, Inc and Alkermes Finance LLC Enters into Credit Agreement - marketscreener.com
Alkermes PLC has successfully completed the acquisition of Avadel Pharmaceuticals plc. - Bitget
Alkermes Completes Acquisition and Delisting of Avadel Pharmaceuticals - TipRanks
Alkermes Acquires Avadel to Expand Product Portfolio - Intellectia AI
Avadel Pharmaceuticals Terminates Multiple Agreements Following Alkermes Acquisition - TradingView
Alkermes (Nasdaq: ALKS) closes Avadel acquisition, adds LUMRYZ and $1.5B loans - Stock Titan
Understanding the Setup: (ALKS) and Scalable Risk - Stock Traders Daily
Alkermes to report fourth quarter and year-end financial results on Feb. 25, 2026 - MSN
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026 - Business Wire
Alkermes earnings up next as sleep strategy takes shape - Investing.com
Irish High Court sanctions Avadel Pharmaceuticals acquisition by Alkermes - TipRanks
Alkermes (ALKS) Set to Finalize Acquisition of Avadel Pharmaceuticals - GuruFocus
Avadel Pharmaceuticals plc Announces High Court Approval of Scheme of Arrangement for Acquisition by Alkermes plc - Quiver Quantitative
Avadel Pharmaceuticals Announces Outcome of the Court Sanction Hearing - The Manila Times
Irish court clears Alkermes buyout; Avadel stock trading ends Feb. 11 - Stock Titan
Alkermes Increases Offer for Avadel Acquisition - MSN
INCY Q4 Earnings Miss Estimates, Revenues Beat on Higher Product Sales - Finviz
History Review: Will Alkermes plc outperform its industry peersJuly 2025 Selloffs & AI Powered Market Entry Ideas - baoquankhu1.vn
Allianz Asset Management GmbH Acquires 511,702 Shares of Alkermes plc $ALKS - MarketBeat
KOD Stock Up 24% in 3 Months: Here's What You Need to Know - Finviz
Stop Loss: Is Alkermes plc benefiting from interest rate changesPrice Action & Community Trade Idea Sharing Platform - baoquankhu1.vn
Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates - Finviz
Alkermes (ALKS) Projected to Post Earnings on Wednesday - MarketBeat
Here's Why Gilead Sciences Stock Surged 21% in a Month - Finviz
Alkermes (NASDAQ:ALKS) Director Sells $2,115,684.00 in Stock - MarketBeat
Alkermes (NASDAQ:ALKS) EVP Craig Hopkinson Sells 9,000 Shares - MarketBeat
Alkermes plc (ALKS) Stock Analysis: Navigating a 29% Potential Upside in the Biopharmaceutical Sector - DirectorsTalk Interviews
Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome - Finviz
Is Alkermes (ALKS) Outperforming Other Medical Stocks This Year? - Yahoo Finance
The Technical Signals Behind (ALKS) That Institutions Follow - Stock Traders Daily
Are options traders betting on a big move in Alkermes stock? - MSN
Alkermes plc $ALKS Shares Sold by Y Intercept Hong Kong Ltd - MarketBeat
Assessing Alkermes (ALKS) Valuation After Its Recent Share Price Momentum - Yahoo Finance
FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug - Finviz
HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance - Finviz
TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth - Finviz
Are Options Traders Betting on a Big Move in Alkermes Stock? - Nasdaq
NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold - Finviz
Alkermes stock price target raised to $47 from $46 at UBS on Avadel deal - Investing.com Nigeria
Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why - Finviz
Why analysts are rating Alkermes (ALKS) a buy - MSN
Jim Cramer on Alkermes: "I Think It's a Hold, Maybe a Weak One" - Finviz
Jim Cramer on Alkermes: “I Think It’s a Hold, Maybe a Weak One” - Insider Monkey
Weekly Earnings: Is Alkermes plc benefiting from interest rate changesQuarterly Trade Report & Verified Entry Point Detection - baoquankhu1.vn
ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission - Finviz
NVO Expands Aspect Tie-Up to Advance Curative Diabetes Cell Therapies - Finviz
Alkermes Plc Stock (ALKS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.70%
10.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):